RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q3 FY25 results · Oct–Dec 2024
RPG Life Sciences reported revenue from operations of ₹172.71 crore (up 12.4% from Q3 FY24) and net profit of ₹34.93 crore (up 32.0% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a standalone basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 172.71 | 153.70 | +12.4% | 172.21 | +0.3% |
| Other income | 3.31 | 1.92 | +72.4% | 1.94 | +70.6% |
| Total income | 176.02 | 155.62 | +13.1% | 174.15 | +1.1% |
| Profit before tax | 46.89 | 35.54 | +31.9% | 15.09 | +210.7% |
| Net profit for the period | 34.93 | 26.46 | +32.0% | 4.20 | +731.7% |
| EPS, basic (₹) | 21.12 | 16.00 | +32.0% | 2.54 | +731.5% |
| Net margin (%) | 20.2 | 17.2 | 2.4 |
Standalone
- Filed with BSE
- 24 Jan 2025, 20:28 IST
- Board meeting
- 24 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE